自体细胞疗法市场－全球产业规模、份额、趋势、机会和预测：来源、应用、终端用户、地区和竞争格局（2021-2031年）

全球自体细胞疗法市场预计将从 2025 年的 63.7 亿美元成长到 2031 年的 89.8 亿美元，复合年增长率为 5.89%。

这种治疗方法包括采集、处理和重新输注患者自身的细胞，以治疗特定疾病，从而有效降低与异体移植相关的免疫排斥风险。推动该市场发展的关键因素是慢性疾病（尤其是肿瘤和自体免疫疾病）的盛行率不断上升，这促使人们对个人化医疗干预的需求日益增长。此外，该领域还受益于有利的法规环境，加速了从临床试验到商业应用的转化。例如，国际细胞与基因治疗学会 (ISCT) 报告称，美国食品药物管理局(FDA) 在 2024 年核准了七种新的细胞和基因治疗产品，凸显了该领域创新和市场准入的快速发展。

儘管取得了这些积极进展，但自体细胞疗法市场在生产扩充性和供应链复杂性方面仍面临许多挑战。这些治疗方法的个人化特点要求进行严格的「静脉到静脉」移植流程，这既耗费人力又对物流要求极高。因此，高昂的生产成本仍然是一大挑战，可能会阻碍自体细胞疗法在全球医疗保健系统中的广泛应用和推广。

市场驱动因素

全球癌症和自体免疫疾病的日益普及是自体细胞疗法市场的主要驱动力，也使得人们迫切需要能够治疗疑难杂症的治疗方法。随着标准疗法在多发性骨髓瘤等复杂疾病中的限制日益凸显，对个人化细胞疗法的需求呈指数级增长。日益加重的疾病负担与治疗方法的推广应用和商业性化规模化直接相关。例如，根据传奇生物于2025年3月发布的《2024年第四季及全年财务报告》，该公司自体CAR-T疗法CarVicty全年销售额达9.63亿美元，并在全球范围内治疗了超过5000名患者。这表明，疑难肿瘤的诊断正在推动这些先进治疗方法融入常规临床实践。

与此同时，CAR-T 和基因工程疗法的监管核准数量激增，加速了市场的成熟。监管机构越来越多地核准早期疗法领域的新型自主研发产品，这不仅证明了其安全性，也开闢了新的收入来源。这一发展势头体现在越来越多的核准治疗方法进入商业市场。根据再生医学联盟 (Alliance for Regenerative Medicine) 2025 年 1 月发布的《产业趋势简报》，预计该领域在 2024 年将获得 9 项监管核准，标誌着从临床开发到市场交付的强劲转型。监管方面的成功正在推动快速的财务成长。正如百时美施贵宝 (Bristol-Myers Squibb) 2025 年 2 月的报告显示，其细胞疗法 Braiange 的全球销售额达到 7.47 亿美元，年成长 105%。

市场挑战

高昂的製造成本，主要源自于产能有限和供应链复杂，严重阻碍了全球自体细胞疗法市场的成长。与传统药物和异体疗法不同，自体细胞疗法依赖患者自身的细胞，因此每剂药物都需要客製化的、劳力密集的生产流程。这种缺乏标准化的现状使得该行业无法实现规模经济，导致产品售价居高不下，进而造成全球医疗体系报销范围有限，患者获取治疗的机会也受到限制。

随着在研治疗方法的增加，生产瓶颈问题日益严峻。根据国际细胞与基因治疗学会（ISCT）预测，到2024年，全球在研治疗方法数量将增至3063种，光上半年就增加了7.5%。临床候选药物的快速累积给本已不堪重负的生产基础设施带来了巨大压力。如果无法有效扩大生产规模以满足不断增长的需求，市场将面临「商业化瓶颈」——即创新治疗方法核准后，却无法以合理的价格或充足的供应量推向市场。

市场趋势

自体CAR-T疗法在自体免疫疾病领域的拓展标誌着市场格局的根本性转变。其应用范围已从肿瘤学扩展到全身性红斑性狼疮和多发性硬化症等严重的治疗。研发人员正利用基因工程改造的T细胞显着清除B细胞并重置免疫系统的能力，为对标准免疫抑制剂抗药性的患者带来功能性治癒的可能性。这种日益增长的临床关注正在迅速建立一个强大的开发平臺，从而降低对癌症治疗的依赖。例如，2024年7月发表在Medscape上的报导《CAR-T细胞在自体免疫疾病中的研究蓬勃发展》报导了约40项正在进行的、利用CAR-T细胞治疗各种自体免疫疾病的研究，这显着地显示了资源正向这一新兴治疗领域转移。

同时，肿瘤浸润淋巴细胞（TIL）疗法的商业化代表着固态肿瘤领域的重大突破，有效地将目标市场拓展至骨髓恶性肿瘤之外。这一趋势涉及采集和激活患者特异性免疫细胞，以靶向治疗传统上难以用细胞疗法治疗的疾病领域（例如转移性黑色素瘤）中复杂的肿瘤微环境。这些新型疗法迅速获得市场关注，也印证了其商业性可行性。根据Iovance Biotherapeutics公司于2024年11月发布的“2024年第三季度及全年财务业绩”，该公司TIL疗法Amtagvi在第三季度于美国创造了4210万美元的净产品收入，展现了固体癌细胞疗法强劲的发展势头。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球自体细胞疗法市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依来源（骨髓、表皮、间质干细胞、造血干细胞、软骨细胞、其他）
  • 依应用领域（癌症、神经退化性疾病、心血管疾病、自体免疫疾病、整形外科、创伤治疗等）
  • 按最终使用者（医院/诊所、门诊中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美自体细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲自体细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区自体细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲自体细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲自体细胞疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球自体细胞疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Biomatrica, Inc.
• Holostem Terapie Avanzate SRL
• Pharmicell Co. Inc
• Caladrius Biosciences Inc
• US Stem Cell Inc
• Bristol Myers Squibb Company
• Corning Incorporated
• Vericel Corporation
• Catalent, Inc
• Sartorius AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Autologous Cell Therapy Market is projected to expand from USD 6.37 Billion in 2025 to USD 8.98 Billion by 2031, reflecting a compound annual growth rate of 5.89%. This therapeutic approach involves the collection, processing, and reintroduction of a patient's own cells to address specific medical conditions, effectively mitigating the immune rejection risks often associated with allogeneic alternatives. A primary catalyst for this market is the increasing prevalence of chronic diseases, specifically oncology and autoimmune disorders, which has heightened the demand for personalized medical interventions. Furthermore, the sector benefits from a supportive regulatory environment that accelerates the transition of therapies from clinical trials to commercial availability; for example, the International Society for Cell & Gene Therapy reported in 2024 that the United States Food and Drug Administration approved seven new cell and gene therapy products, highlighting the rapid pace of innovation and market entry.

Despite these positive developments, the market encounters significant hurdles regarding production scalability and supply chain complexity. The personalized nature of these treatments necessitates a rigorous "vein-to-vein" process that is both labor-intensive and logistically demanding. Consequently, high manufacturing costs remain a substantial challenge, potentially hindering the widespread adoption and expansion of autologous cell therapies across global healthcare systems.

Market Driver

The rising global prevalence of cancer and autoimmune disorders acts as the primary engine for the autologous cell therapy market, creating an urgent need for treatments capable of addressing refractory conditions. As the limitations of standard care become evident in complex indications such as multiple myeloma, the demand for personalized cellular interventions is increasing sharply. This growing disease burden is translating directly into significant therapy adoption and commercial volume; for instance, Legend Biotech's "Fourth Quarter and Full Year 2024 Financial Results" in March 2025 reported that its autologous CAR-T therapy, Carvykti, generated $963 million in full-year sales and treated over 5,000 patients globally, demonstrating how persistent oncological diagnoses are driving the integration of these advanced modalities into routine clinical practice.

Simultaneously, a surge in regulatory approvals for CAR-T and gene-modified therapies is accelerating market maturity. Regulatory bodies are increasingly clearing novel autologous products for earlier lines of therapy, thereby validating their safety profiles and opening new revenue streams. This momentum is reflected in the growing volume of approved therapies entering the commercial space; according to the Alliance for Regenerative Medicine's "State of the Industry Briefing" in January 2025, the sector secured nine regulatory approvals in 2024, signaling a robust shift from clinical development to market availability. This regulatory success is fueling rapid financial growth, as evidenced by Bristol Myers Squibb's February 2025 report, which noted that global revenue for its cell therapy Breyanzi reached $747 million, marking a 105% increase compared to the previous year.

Market Challenge

The high cost of manufacturing, driven by limited scalability and supply chain complexity, presents a formidable barrier to the growth of the Global Autologous Cell Therapy Market. Unlike traditional pharmaceutical or allogeneic treatments, autologous therapies rely on a patient's own cells, necessitating a bespoke, labor-intensive manufacturing process for each individual dose. This lack of standardization prevents the industry from achieving economies of scale, resulting in exorbitant costs of goods sold that restrict reimbursement potential and limit patient access within global healthcare systems.

This production bottleneck is becoming increasingly critical as the volume of developing treatments grows. According to the International Society for Cell & Gene Therapy, the global pipeline expanded in 2024 to include 3,063 active therapies, representing a 7.5 percent increase in the first half of the year alone. This rapid accumulation of clinical candidates places immense pressure on an already strained manufacturing infrastructure. Without the capacity to efficiently scale production to meet this rising demand, the market faces a "commercialization bottleneck" where innovative therapies are approved but cannot be delivered at a viable price point or volume.

Market Trends

The expansion of autologous CAR-T therapies into autoimmune indications marks a fundamental market pivot, extending beyond oncology to treat severe conditions such as systemic lupus erythematosus and multiple sclerosis. Developers are harnessing the ability of engineered T-cells to deeply deplete B-cells and reset the immune system, offering a potential functional cure for patients refractory to standard immunosuppressants. This intensifying clinical focus is rapidly building a robust development pipeline that diversifies the sector's reliance on cancer treatments; for example, a July 2024 Medscape article titled "CAR T-Cell Studies in Autoimmune Diseases Are Proliferating" noted approximately 40 active studies utilizing CAR-T cells across various autoimmune indications, reflecting a significant resource shift toward this new therapeutic frontier.

Concurrently, the commercialization of Tumor-Infiltrating Lymphocyte (TIL) therapies represents a critical breakthrough in the solid tumor segment, effectively widening the addressable market beyond hematological malignancies. This trend involves extracting and invigorating patient-specific immune cells to target complex cancer microenvironments in indications like metastatic melanoma, which have historically been difficult to treat with cellular modalities. The immediate market traction of these novel therapies underscores their commercial viability; according to Iovance Biotherapeutics' "Third Quarter and Year to Date 2024 Financial Results" from November 2024, the company's TIL therapy Amtagvi generated $42.1 million in U.S. net product revenue during the third quarter, signaling a strong adoption trajectory for solid tumor cell therapies.

Key Market Players

• Biomatrica, Inc.
• Holostem Terapie Avanzate S.R.L
• Pharmicell Co. Inc
• Caladrius Biosciences Inc
• U.S. Stem Cell Inc
• Bristol Myers Squibb Company
• Corning Incorporated
• Vericel Corporation
• Catalent, Inc
• Sartorius AG

Report Scope

In this report, the Global Autologous Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autologous Cell Therapy Market, By Source

• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Haematopoietic Stem Cells
• Chondrocytes
• Others

Autologous Cell Therapy Market, By Application

• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Others

Autologous Cell Therapy Market, By End User

• Hospitals & Clinics
• Ambulatory Centers
• Others

Autologous Cell Therapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autologous Cell Therapy Market.

Available Customizations:

Global Autologous Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Autologous Cell Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Haematopoietic Stem Cells, Chondrocytes, Others)
  • 5.2.2. By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Autologous Cell Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Autologous Cell Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Autologous Cell Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Autologous Cell Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Autologous Cell Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Autologous Cell Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Autologous Cell Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Autologous Cell Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Autologous Cell Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Autologous Cell Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Autologous Cell Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Autologous Cell Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Autologous Cell Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Autologous Cell Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Autologous Cell Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Autologous Cell Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Autologous Cell Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Autologous Cell Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Autologous Cell Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Autologous Cell Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Autologous Cell Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Autologous Cell Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Autologous Cell Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Autologous Cell Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Autologous Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biomatrica, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Holostem Terapie Avanzate S.R.L
• 15.3. Pharmicell Co. Inc
• 15.4. Caladrius Biosciences Inc
• 15.5. U.S. Stem Cell Inc
• 15.6. Bristol Myers Squibb Company
• 15.7. Corning Incorporated
• 15.8. Vericel Corporation
• 15.9. Catalent, Inc
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer